19,997 Shares in ChromaDex Co. (NASDAQ:CDXC) Acquired by Franklin Resources Inc.

Franklin Resources Inc. purchased a new stake in ChromaDex Co. (NASDAQ:CDXC) during the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 19,997 shares of the company’s stock, valued at approximately $68,000.

A number of other institutional investors and hedge funds also recently modified their holdings of CDXC. WINTON GROUP Ltd acquired a new position in shares of ChromaDex in the 2nd quarter worth $597,000. Bank of New York Mellon Corp boosted its position in shares of ChromaDex by 170.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after purchasing an additional 119,915 shares during the period. BSW Wealth Partners purchased a new position in ChromaDex in the 3rd quarter worth about $324,000. BNP Paribas Financial Markets raised its holdings in ChromaDex by 1,885.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company’s stock worth $267,000 after buying an additional 69,582 shares during the period. Finally, State Street Corp lifted its stake in ChromaDex by 11.3% during the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after buying an additional 62,692 shares in the last quarter. Institutional investors and hedge funds own 15.41% of the company’s stock.

ChromaDex Stock Up 3.4 %

Shares of NASDAQ:CDXC opened at $5.48 on Friday. ChromaDex Co. has a 12-month low of $1.36 and a 12-month high of $7.97. The firm has a market capitalization of $418.58 million, a P/E ratio of 548.55 and a beta of 2.15. The firm has a fifty day moving average of $6.25 and a two-hundred day moving average of $4.23.

ChromaDex (NASDAQ:CDXC) last issued its earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The company had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same period in the prior year, the firm posted ($0.01) EPS. Equities research analysts expect that ChromaDex Co. will post 0.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CDXC has been the topic of several analyst reports. Roth Mkm lifted their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. HC Wainwright lifted their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Finally, StockNews.com raised shares of ChromaDex from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, December 25th.

Insider Activity

In other news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the transaction, the director now directly owns 244,179 shares in the company, valued at $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.64% of the stock is currently owned by insiders.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.